Soluble receptor for advanced glycation end products predicts 28-day mortality in critically ill patients with sepsis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 73, Issue 8, 2013, Pages 650-660

  Brodska, Helena ^a   Malickova, Karin ^a   Valenta, Jiri ^b   Fabio, Anthony ^c   Drabek, Tomas ^d  

^a Institute of Clinical Biochemistry and Laboratory Diagnostics   (Switzerland)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; C reactive protein; Procalcitonin; Sepsis; Soluble receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; CREATININE; LACTIC ACID; PROCALCITONIN;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORGAN INJURY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SEPSIS; SURVIVOR;

ACUTE KIDNEY INJURY; ADULT; BIOLOGICAL MARKERS; CRITICAL ILLNESS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 84887579605     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2013.849357     Document Type: Article

References (45)

1. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010;14:R15.
2. Vincent JL, Donadello K, Schmit X. Biomarkers in the critically ill patient: C-reactive protein. Crit Care Clin 201 1;27:241-51.
3. Reinhart K, Meisner M. Biomarkers in the critically ill patient: procalcitonin. Crit Care Clin 2011;27:253-63.
4. Hochreiter M, Schroeder S. [Procalcitonin-based algorithm. Management of antibiotic therapy in critically ill patientsj. Anaesthesist 2011;60:661-73.
5. Hochreiter M, Kohler T, Schweiger AM, Keck FS, Bein B, von SpiegelT, Schroeder S. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009;13:R83.
6. Reinhart K, Hartog CS. Biomarkers as a guide for antimicrobial therapy. Tnt J Antimicrob Agents 2010;36(Suppl. 2) :S 17-2 1.
7. Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2010;2010:917108.
8. Bopp C, Bierhaus A, Hofer 5, Bouchon A, Nawroth PP, Martin E, Weigand M.A. Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care 2008; 12: 20 1.
9. Bopp C, Hofer 5, Weitz J, Bierhaus A, Nawroth PP, Martin E, Buchler MW, Weigand MA. sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008; 147:79-83 (Pubitemid 351626081)
10. Kikkawa T, Sato N, Kojika M, Takahashi G, Aoki K, Hoshikawa K, Akitomi 5, Shozushima T, Suzuki K, Wakabayashi G, Endo S. Significance of measuring 51 OOA1 2 and sRAGE in the serum of sepsis patients with postoperative acute lung injury. Dig Surg 2010;27:307-12.
11. Yamagishi 5, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2010;2:1184-95.
12. Miniati M, Monti 5, Basta G, Cocci F, Fornai E, Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res 2011;12:37.
13. Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J 2011;37:516-22.
14. Calfee CS, Budev MM, Matthay MA, Church G, Brady 5, Uchida T, Ishizaka A, Lara A, Ranes JL, deCamp MM, Arroliga AC. Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation. J Heart Lung Transplant 2007;26 :675-80. (Pubitemid 47001705)
15. Jabaudon M, Futier E, Roszyk L, Chalus E, Guerin R, Petit A, Mrozek 5, Perbet 5, Cayot-Constantin 5, Chartier C, SapinV, Bazin JE, Constantin JM. Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients. Crit Care Med 2011;39:480-8.
16. Jing R, Cui M, Wang J, Wang H. Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma 2010;57: 55-6 1.
17. Mauri T, Masson 5, Pradella A, Bellani G, Coppadoro A, Bombino M, Valentino 5, Patroniti N, Mantovani A, Pesenti A, Latini R. Elevated plasma and alveolar levels of soluble receptor for advanced glycation endproducts are associated with severity of lung dysfunction in ARDS patients. Tohoku J Exp Med 2010;222:105-12.
18. Liu X, Chen Q, Shi 5, Shi Z, Lin R, Tan L, Yu J, Shu Q, Fang X. Plasma sRAGE enables prediction of acute lung injury after cardiac surgery in children. Crit Care 2012; 16 :R9 1.
19. Raposeiras-Roubin 5, Rodino-Janeiro BK, GrigorianShamagian L, Moure-Gonzalez M, Seoane-Blanco A, Varela-Roman A, Alvarez E, Gonzalez-Juanatey JR. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: new roles for soluble RAGE. Eur J Heart Fail 2010;12:1092-100.
20. Selejan SR, Poss J, Hewera L, Kazakov A, Bohm M, Link A. Role of receptor for advanced glycation end products in cardiogenic shock. Crit Care Med 2012;40:1513-22.
21. Kalousova M, Hodkova M, Kazderova M, Fialova J, Tesar V, Dusilova-Sulkova 5, Zima T. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006;47:406-11. (Pubitemid 43255173)
22. Cohen MJ, Carles M, Brohi K, Calfee CS, Rahn P, Call MS, Chesebro BB, West MA, Pittet JF. Early release of soluble receptor for advanced glycation endproducts after severe trauma in humans. JTrauma 2010;68:1273-8.
23. American College of Chest Physicians Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
24. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCMIESICMIACCP ATS SIS International Sepsis Definitions Conference. Intensive Care Med 2003;29:530-8. (Pubitemid 36523666)
25. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
26. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR. Morris A, Spragg R. Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensive Care Med 1994;20:225-32. (Pubitemid 24088590)
27. Krechler T, Jachymova M, Mestek 0, Zak A, Zima T, Kalousova M. Soluble receptor for advanced glycation end- products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin Biochem 2010;43:882-6.
28. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
29. Metz CE. Basic principles of ROC analysis. Seminars in nuclear medicine 1 978;8 :283-98. (Pubitemid 9075026)
30. Punyadeera C, Schneider EM, Schaffer D, Hsu HY, Joos TO, Kriebel F, Weiss M, Verhaegh WF. A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. J Emerg Trauma Shock 2010;3:26-35.
31. Karlsson 5, Heikkinen M, Pettila V, Alila 5, Vaisanen 5, Pulkki K, Kolho E, Ruokonen E. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care 2010;14:R205.
32. Vincent JL, Moreno R. Clinical review: scoring systems in the critically ill. Crit Care 2010;14:207.
33. Ho KM, Lee KY, Williams T, Finn J, Knuiman M,Webb SA. Comparison of Acute Physiology and Chronic Health Evaluation (APACHE) II score with organ failure scores to predict hospital mortality. Anaesthesia 2007;62:466-73. (Pubitemid 46915698)
34. Minne L, Abu-Hanna A, de Jonge E. Evaluation of SOFA- based models for predicting mortality in the ICU: a systematic review. Crit Care 2008;12:R161.
35. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer 5, Plachky J, Grone HJ, Kurschus FC, Schmidt AM, Yan SD, Martin E, Schleicher E, Stern DM, Hammerling GG, Nawroth PP, Arnold B. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113:1641-50. (Pubitemid 39071688)
36. Raucci A, Cugusi 5, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM1O). Faseb J 2008;22:3716-27.
37. Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, Nawroth PP, Bierhaus A, Postina R. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 2008;283:35507-16.
38. Zhang H, Tasaka 5, Shiraishi Y, Fukunaga K, Yamada W, Seki H, Ogawa Y, Miyamoto K, Nakano Y, Hasegawa N, MiyashoT, Maruyama I, Ishizaka A. Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. Am J Respir Crit Care Med 2008;178:356-62.
39. Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP. Advanced glycation end product receptormediated cellular dysfunction. Ann NY Acad Sci 2005; 1043:676-80. (Pubitemid 41123959)
40. Lutterloh EC, Opal SM, Pittman DD, Keith JC Jr,Tan XY, Clancy BM, Palmer H, Milarski K, SunY, PalardyJE, Parejo NA, Kessimian N. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007;11:R122.
41. Su X, Looney MR, Gupta N, Matthay MA. Receptor for advanced glycation end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury. Am J Physiol Lung Cell Mol Physiol 2009;297:L1-5.
42. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda 5, Yamagishi S. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. Clin Biochem 2011; 44:601-4.
43. Narvaez-Rivera RM, Rendon A, Salinas-Carmona MC, Rosas-Taraco AG. Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis. BMC Infect Dis 2012;12:15.
44. Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Barany P, Heimburger 0, Stenvinkel P, Lindholm B. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the promflammatory RAGE ligand (EN-RAGE, 51 OOA1 2) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010;5:2213-Q.
45. Raposeiras-Roubin 5, Rodino-Janeiro BK, GrigorianShamagian L, Moure-Gonzalez M, Seoane-Blanco A, Varela-Roman A, Almenar-Bonet L, Alvarez E, GonzalezJuanatey JR. Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle heart failure score. Am J Cardiol 2011;107:938-44.